ABL Bio's early-stage clinical drug candidate ‘ABL111’ is highly likely to become the Best in Class within its category. This reflects the excellent clinical results of ABL111 and the significant medical demand for it.
On the 19th, Weijiu, a researcher at Korea Investment & Securities, stated in a report, "ABL111 demonstrated superior efficacy and safety compared to the competing drug zolbetuximab in early clinical results," adding, "Its efficacy was about twice that of zolbetuximab, and the incidence of adverse events was 17 percentage points lower."
ABL111 is a bispecific antibody pipeline jointly developed by ABL Bio and Nasdaq-listed company iMab. It is a bispecific antibody that stimulates T cells (immune cells) to kill cancer cells and is being developed as a treatment for gastric cancer and other indications.
Bispecific antibody therapeutics refer to drugs that treat diseases by simultaneously binding two antigens with a single antibody. They have higher therapeutic effects than single antibodies and have recently gained attention alongside antibody-drug conjugates (ADC).
Researcher Weijiu noted, "The target antigen of ABL111, CLDN18.2, is highly expressed in gastric cancer and other cancers," adding, "Gastric cancer ranks fifth among causes of cancer death and has a large unmet medical need (demand arising from a severe shortage of supply relative to treatment needs)." He also pointed out, "Although immune checkpoint inhibitors Keytruda and Opdivo have been approved by the U.S. Food and Drug Administration (FDA) as first-line treatments, their efficacy is insufficient."
He further explained, "ABL111 can be used in triple combination clinical trials along with immune checkpoint inhibitors and chemotherapy," and "ABL Bio is currently conducting triple combination clinical trials to enter the first-line treatment market for ABL111 and is planning a Phase 2 clinical trial to obtain approval as a third-line treatment."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
